GSK’s Post-Advair Day Has Dawned, But Breo And Anoro Not Yet Shining
This article was originally published in The Pink Sheet Daily
Executive Summary
Decline in Advair sales to cointinue for several years as the portfolio transitions to new products, which have faced reimbursement challenges.
You may also be interested in...
China Scandal One Early Challenge For New GSK Chairman
Philip Hampton likely will have to deal with the fallout from the Chinese bribery scandal, as well as a major restructuring of the previously announced asset swap with Novartis, and increasing generic competition to its leading products.
Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.
Emerging Markets Earnings Roundup: GlaxoSmithKline (Part 4)
GlaxoSmithKline CEO Andrew Witty took a question on the China compliance investigation and quickly moved on in an earnings call also thin on emerging market plans. However, the earnings release added a bit of detail on both fronts, including up-to-date details on regulatory aspects outside of China.